Mario Pizzini, MD
Neurology · Bozeman, MTNPI 1871868042
Payments from drug & device makers
What this record shows
13 manufacturers reported payments, led by Boston Scientific at 59.7% of the total. Reporting peaked in 2024 at $2,154 and has fallen 69.3% since, to $662 in 2025.
Across 57 payments — averaging $52.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Teva Pharmaceuticals USA, Inc.$544
- Pfizer$172
- Livanova USA, Inc.$87
- Bristol Myers Squibb$76
- AstraZeneca$74
- plus $247 from 7 others
What the payments were for
- Travel & lodging$1,51251%
- Food & beverage$1,46349%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 7 | $1,775 |
| Teva Pharmaceuticals USA, Inc. | 21 | $544 |
| Pfizer | 10 | $172 |
| Livanova USA, Inc. | 1 | $87 |
| Bristol Myers Squibb | 5 | $76 |
| AstraZeneca | 3 | $74 |
| Argenx US, Inc. | 2 | $53 |
| AbbVie | 2 | $52 |
| Medtronic | 1 | $41 |
| Ipsen Biopharmaceuticals, Inc | 1 | $35 |
| Biogen | 2 | $30 |
| Genentech USA, Inc. | 1 | $21 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERCISE$1,538
How this compares
$2,975 in reported general payments places this provider in the 60th percentile of 48 neurology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 38 | $66,695 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 277 | $16,990 |
| Lacosamide | 30 | $14,428 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $10,518 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $9,374 |
| Rasagiline Mesylate | 29 | $4,375 |
| Lamotrigine | 114 | $4,049 |
| Levetiracetam | 106 | $3,886 |
| Gabapentin | 95 | $2,377 |
| Ropinirole Hcl | 32 | $2,141 |
| AmantadineAmantadine Hcl | 49 | $2,137 |
| Zonisamide | 90 | $1,918 |
| Primidone | 37 | $1,861 |
| Baclofen | 52 | $1,747 |
| Divalproex Sodium | 48 | $1,609 |
Paid to pharmacies, not to this prescriber.
Other neurology in Bozeman
- Emily PharrBozeman$14K
- David LoranceBozeman$534
- Matthew BainBozeman$200
- James RaglandBozeman$194
- Richard PopwellBozeman$62
- Joshua KnappenbergerBozeman$51
- Ann CollierBillings$164K
- Dennis DietrichGreat Falls$140K
- Nicole ClarkHelena$85K
- Kristian FrenchBillings$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.